{"id":1542,"date":"2023-10-12T14:51:56","date_gmt":"2023-10-12T18:51:56","guid":{"rendered":"https:\/\/www.orbimed.com\/%e4%b8%bb%e9%a1%b5\/"},"modified":"2026-10-02T15:29:44","modified_gmt":"2026-10-02T19:29:44","slug":"homepage","status":"publish","type":"page","link":"https:\/\/www.orbimed.com\/zh\/","title":{"rendered":"Homepage (CH)"},"content":{"rendered":"
\n
\n \"\"\n <\/div>\n
\n
\n

\u521b\u9020\u751f\u7269\u533b\u7597\u7684\u672a\u6765<\/h1>\n \n
\n

\u5965\u535a\u8d44\u672c\u81f4\u529b\u4e8e\u5728\u5168\u7403\u8303\u56f4\u5185\u6295\u8d44\u4e16\u754c\u4e00\u6d41\u7684\u751f\u7269\u533b\u7597\u516c\u53f8\uff0c\u63a8\u52a8\u521b\u65b0\uff0c\u89e3\u51b3\u6709\u5f85\u6ee1\u8db3\u7684\u533b\u7597\u9700\u6c42\uff0c\u63d0\u5347\u60a3\u8005\u6cbb\u7597\u6548\u679c\u3002<\/p>\n <\/div>\n \n <\/div>\n <\/div>\n

<\/div>\n
<\/div>\n<\/section>\n\n\n
\n
\n
\n
\n \"\"\n
\n
\n \n \n <\/svg>\n <\/div>\n
\n \n \n <\/svg>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n
\n

\u91cf\u8eab\u5b9a\u5236\u7684\u878d\u8d44\u65b9\u6848\u548c\u5168\u7403\u56e2\u961f\uff0c\u5e2e\u52a9\u521b\u5efa\u4e16\u754c\u4e00\u6d41\u7684\u751f\u7269\u533b\u7597\u516c\u53f8\u3002<\/h2>\n \n

\u4ece\u751f\u7269\u5236\u836f\u5230\u533b\u7597\u5668\u68b0\u3001\u6570\u5b57\u5065\u5eb7\u3001\u8bca\u65ad\u548c\u533b\u7597\u670d\u52a1\uff0c\u5965\u535a\u8d44\u672c\u81f4\u529b\u4e8e\u5728\u5168\u7403\u8303\u56f4\u5185\u5bfb\u627e\u80fd\u591f\u4f7f\u4eba\u7c7b\u751f\u6d3b\u5f97\u66f4\u5065\u5eb7\u548c\u66f4\u957f\u4e45\u7684\u521b\u65b0\u9879\u76ee\u3002<\/p>\n

\u6211\u4eec\u6df1\u8015\u5168\u7403\u533b\u7597\u4fdd\u5065\u884c\u4e1a\u6295\u8d44\u4e8c\u5341\u4f59\u8f7d\uff1a\u4ece\u521d\u521b\u79c1\u8425\u516c\u53f8\u5230\u5927\u578b\u8de8\u56fd\u4f01\u4e1a\u3002\u6211\u4eec\u7684\u56e2\u961f\u7531150\u4f59\u540d\u6770\u51fa\u4e13\u4e1a\u4eba\u58eb\u7ec4\u6210\uff0c\u5176\u4e13\u4e1a\u80cc\u666f\u8986\u76d6\u79d1\u5b66\u3001\u533b\u5b66\u548c\u6295\u8d44\u7b49\u9886\u57df\u3002\u5965\u535a\u8d44\u672c\u5728\u5168\u7403\u8303\u56f4\u5185\u7ba1\u7406\u8d44\u4ea7\u903e210\u4ebf\u7f8e\u5143\u3002<\/p>\n\n \u6211\u4eec\u5982\u4f55\u6295\u8d44<\/a>\n <\/div>\n <\/div>\n <\/section>\n \n\n

\n
\n
\n
\n \"\"\n
\n
\n \n \n <\/svg>\n <\/div>\n
\n \n \n <\/svg>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n
\n

\u4e86\u89e3\u6211\u4eec\u7684\u533b\u7597\u521b\u65b0\u516c\u53f8<\/h2>\n \n
\n
\n
\n \"port-co\"\n \n

Messenger RNA targeting to create life-saving therapeutics<\/h3>\n \n

ADARx is developing a proprietary RNA targeting platform, including oligonucleotides for inhibition, degradation, and editing, together with novel oligonucleotide delivery technologies.<\/p>\n \n Learn More<\/a>\n <\/div>\n <\/div>\n

\n
\n \"Port-co\"\n \n

Pushing targeted oncology drug discovery to new heights<\/h3>\n \n

Treeline Biosciences is pursuing molecular targets in oncology that are validated but difficult to drug, leveraging its four pillars of drug discovery: mechanistic biology, medicinal chemistry, computational science, and structural biology and protein science.<\/p>\n \n Learn More<\/a>\n <\/div>\n <\/div>\n

\n
\n \"PortCo\"\n \n

Redefining Immunology and Inflammation with Precision<\/h3>\n \n

Mirador Therapeutics envisions a bold new era of precision medicine for immune-mediated inflammatory and fibrotic diseases driven by speed and better development accuracy.<\/p>\n \n Learn More<\/a>\n <\/div>\n <\/div>\n

\n
\n \"port-co\"\n \n

At the forefront of breakthrough science<\/h3>\n \n

Insmed Incorporated is a commercial-stage global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company commercializes two approved therapies to treat chronic, debilitating lung diseases \u2013 ARIKAYCE\u00ae (amikacin liposome inhalation suspension) for the treatment of refractory MAC lung disease, and BRINSUPRI\u00ae (brensocatib) for the treatment of non-cystic fibrosis bronchiectasis. Insmed is also advancing a diverse portfolio of mid- to late-stage investigational medicines organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. The Company\u2019s research engine is advancing a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue, in the pursuit of future pipeline candidates.<\/p>\n \n Learn More<\/a>\n <\/div>\n <\/div>\n

\n
\n \"Baili\n \n

A Global Leader in Antibody and ADC Oncology Therapies<\/h3>\n \n

Biokin is a clinical-stage company developing innovative ADCs, bi-specific, and multi-specific antibodies for the treatment of cancers. By targeting multiple signaling pathways, Biokin is seeking to overcome the insufficient anti-tumor responses typical of existing mono-antibody therapies.<\/p>\n \n Learn More<\/a>\n <\/div>\n <\/div>\n

\n
\n \"Avenzo\n \n

Taking a leading approach to tackle the complexities of cancer<\/h3>\n \n

Avenzo Therapeutics is a clinical-stage biotechnology company focused on developing next-generation oncology therapies for patients. The company\u2019s pipeline includes potential best-in-class small molecules and antibody-drug conjugates (ADCs).<\/p>\n \n Learn More<\/a>\n <\/div>\n <\/div>\n <\/div>\n \n

\n \u67e5\u770b\u5168\u90e8<\/a>\n <\/div>\n \n \n <\/div>\n <\/div>\n<\/section>\n\n\n
\n
\n
\n

$21<\/span>B<\/h3>\n \n

\u8d44\u4ea7\u7ba1\u7406\u89c4\u6a21\u8fbe210\u4ebf\u7f8e\u5143<\/p>\n <\/div>\n

\n

500<\/span>+<\/h3>\n \n

\u591a\u5bb6\u6295\u8d44\u7ec4\u5408\u516c\u53f8<\/p>\n <\/div>\n

\n

150<\/span>+<\/h3>\n \n

\u4f59\u540d\u4e13\u4e1a\u4eba\u58eb<\/p>\n <\/div>\n

\n

12<\/span><\/h3>\n \n

\u4e2a\u5168\u7403\u529e\u516c\u5ba4<\/p>\n <\/div>\n

\n

130<\/span>+<\/h3>\n \n

\u4e2a IPO<\/p>\n <\/div>\n <\/div>\n

<\/div>\n<\/section>\n\n\n
\n
\n
\n

\u65b0\u95fb\u548c\u89c1\u89e3<\/h2>\n \n \u67e5\u770b\u5168\u90e8<\/a>\n <\/div>\n\n
\n
\n
\n \"\"\n <\/div>\n\n

Orbimed News<\/h3>\n \n

OrbiMed jumps to number one on the Endpoints top 100 list of biotech venture…<\/p>\n Read More<\/a>\n link<\/span><\/a>\n <\/div>\n

\n
\n \"OrbiMed\n <\/div>\n\n

\u5965\u535a\u8d44\u672c<\/h3>\n \n

OrbiMed Raises $1.86 Billion for Healthcare Royalty & Credit Fund V<\/p>\n Read More<\/a>\n link<\/span><\/a>\n <\/div>\n

\n
\n \"Perfuse\n <\/div>\n\n

Portfolio News<\/h3>\n \n

Bayer to acquire Perfuse Therapeutics to complement ophthalmology pipeline<\/p>\n Read More<\/a>\n link<\/span><\/a>\n <\/div>\n <\/div>\n

\n
\n
\n <\/div>\n\n

Orbimed News<\/h3>\n \n

OrbiMed jumps to number one on the Endpoints top 100 list of biotech venture…<\/p>\n Read More<\/a>\n link<\/span><\/a>\n <\/div>\n

\n
\n <\/div>\n\n

\u5965\u535a\u8d44\u672c<\/h3>\n \n

OrbiMed Raises $1.86 Billion for Healthcare Royalty & Credit Fund V<\/p>\n Read More<\/a>\n link<\/span><\/a>\n <\/div>\n

\n
\n <\/div>\n\n

Portfolio News<\/h3>\n \n

Bayer to acquire Perfuse Therapeutics to complement ophthalmology pipeline<\/p>\n Read More<\/a>\n link<\/span><\/a>\n <\/div>\n <\/div>\n <\/div>\n<\/section>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"class_list":["post-1542","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\nHomepage (CH) - OrbiMed<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.orbimed.com\/zh\/\" \/>\n<meta property=\"og:locale\" content=\"zh_HK\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Homepage (CH) - OrbiMed\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.orbimed.com\/zh\/\" \/>\n<meta property=\"og:site_name\" content=\"OrbiMed\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-02T19:29:44+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.orbimed.com\\\/zh\\\/\",\"url\":\"https:\\\/\\\/www.orbimed.com\\\/zh\\\/\",\"name\":\"Homepage (CH) - OrbiMed\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.orbimed.com\\\/zh\\\/#website\"},\"datePublished\":\"2023-10-12T18:51:56+00:00\",\"dateModified\":\"2026-10-02T19:29:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.orbimed.com\\\/zh\\\/#breadcrumb\"},\"inLanguage\":\"zh-HK\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.orbimed.com\\\/zh\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.orbimed.com\\\/zh\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.orbimed.com\\\/zh\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Homepage (CH)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.orbimed.com\\\/zh\\\/#website\",\"url\":\"https:\\\/\\\/www.orbimed.com\\\/zh\\\/\",\"name\":\"OrbiMed\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.orbimed.com\\\/zh\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-HK\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Homepage (CH) - OrbiMed","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.orbimed.com\/zh\/","og_locale":"zh_HK","og_type":"article","og_title":"Homepage (CH) - OrbiMed","og_url":"https:\/\/www.orbimed.com\/zh\/","og_site_name":"OrbiMed","article_modified_time":"2026-10-02T19:29:44+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.orbimed.com\/zh\/","url":"https:\/\/www.orbimed.com\/zh\/","name":"Homepage (CH) - OrbiMed","isPartOf":{"@id":"https:\/\/www.orbimed.com\/zh\/#website"},"datePublished":"2023-10-12T18:51:56+00:00","dateModified":"2026-10-02T19:29:44+00:00","breadcrumb":{"@id":"https:\/\/www.orbimed.com\/zh\/#breadcrumb"},"inLanguage":"zh-HK","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.orbimed.com\/zh\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.orbimed.com\/zh\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.orbimed.com\/zh\/"},{"@type":"ListItem","position":2,"name":"Homepage (CH)"}]},{"@type":"WebSite","@id":"https:\/\/www.orbimed.com\/zh\/#website","url":"https:\/\/www.orbimed.com\/zh\/","name":"OrbiMed","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.orbimed.com\/zh\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-HK"}]}},"_links":{"self":[{"href":"https:\/\/www.orbimed.com\/zh\/wp-json\/wp\/v2\/pages\/1542","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.orbimed.com\/zh\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.orbimed.com\/zh\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.orbimed.com\/zh\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.orbimed.com\/zh\/wp-json\/wp\/v2\/comments?post=1542"}],"version-history":[{"count":3,"href":"https:\/\/www.orbimed.com\/zh\/wp-json\/wp\/v2\/pages\/1542\/revisions"}],"predecessor-version":[{"id":3377,"href":"https:\/\/www.orbimed.com\/zh\/wp-json\/wp\/v2\/pages\/1542\/revisions\/3377"}],"wp:attachment":[{"href":"https:\/\/www.orbimed.com\/zh\/wp-json\/wp\/v2\/media?parent=1542"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}